We use cookies to deliver our services. By visiting our website, you agree to the use of cookies as described in our
Privacy Policy
Daijob.com is Japan's definitive job site for multilingual professionals.
Job Search
- Japan's No1 job site for multilinguals・Job Details 「Daijob.com] TOP
- Other・Jobs in Japan search results
- ステラファーマ株式会社・Company profile TOP
Recruitment for this position has ended.
Company Information
Employer ステラファーマ株式会社
| Company Name | ステラファーマ株式会社 |
|---|---|
| Country of Company HQ | Japan |
| Location of Company | Japan |
| Company Intro |
 BNCT is a type of cancer treatment that combines a neutron irradiation device and a boron drug, and is characterized by the fact that it can be performed in one session or one day. It is a new concept cancer treatment that has been led by Japanese researchers, especially among those being studied around the world. Kansai in particular was a rare region where BNCT research institutes in various fields such as medicine, pharmacy, and physics were concentrated, centered around the Kyoto University Integrated Nuclear Research Institute, which has one of the world's leading clinical research achievements. Stella Chemifa, an affiliated company (then parent company) that manufactures boron 10, essential for BNCT, is based in Osaka, so it was inevitable that we would encounter BNCT and be involved in its development, and Stella Pharma was born. Research on cancer treatment is conducted every day all over the world, but there is still no treatment that can reliably aim for a complete cure with a single method, and the current situation is that multidisciplinary treatment combining various treatments is being performed. Stella Pharma has been involved in the practical application of BNCT, a new radiation therapy, since starting operations in Osaka in 2007, in order to make it play a part in multidisciplinary treatment, and in May 2020, we launched the world's first boron drug for BNCT. We believe that this new step we have taken as a pharmaceutical company marks the beginning of the next stage of BNCT. We will continue to take on challenges to spread "a new tool of light for people fighting cancer" throughout the world, and aim to become a trusted company by providing a stable supply of pharmaceuticals that are needed and safe to use in the medical field. As a pioneer in the development of boron drugs for BNCT, we recognize that we have a corresponding social responsibility. We were listed on the Tokyo Stock Exchange in April 2021. We will continue to operate our business and, under a sound management system, strive to improve the recognition and social credibility of BNCT and our company. |
| Industry | Other |
| Location | Head Office Address: ORIX Koraibashi Building 8F, 3-2-7 Koraibashi, Chuo-ku, Osaka, Osaka Prefecture Tokyo Office Address: Marunouchi Kitaguchi Building 9F, WeWork Marunouchi Kitaguchi, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo |
| President | Yuki Uehara |
| Year of Establishment | 2007 |
| Capital | 3 billion yen |
| Number of Employees | 44 |
| Description of Business | ・Manufacture, sale, research and development of drugs such as those used in neutron capture therapy (BNCT) using boron compounds |
| Work Location (Nearest Station) |
Subway Midosuji Line/Yodoyabashi Station JR Line/Tokyo Station |
| URL | http://www.stella-pharma.co.jp/ |
